发现了强效,高度选择性和口服生物可用的XIa因子抑制剂,用于抗凝治疗
Yajing Zhang1, Rong Huang1, Xueqin Hu1
1Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.
European journal of medicinal chemistry
|February 26, 2025
概括
新的XIa因子 (FXIa) 抑制剂在治疗血栓形成方面表现出高强度和选择性. 化合物43在降低血栓形成而没有增加出血风险方面表现出卓越的疗效,这表明它作为一种新型抗凝剂的潜力.
科学领域:
- 药理学 药理学 是一个学科.
- 药用化学 医学化学
- 心血管研究研究心血管研究
背景情况:
- XIa因子 (FXIa) 是抗凝剂的关键点,因为它在血栓形成中的作用和降低出血的潜力.
- 目前的FXIa抑制剂正在临床试验中,但没有得到批准,这凸显了对新疗法选择的需求.
研究的目的:
- 开发新的,口服生物可用和高度选择性的FXIa抑制剂.
- 为了评估新的FXIa抑制剂的疗效和安全性,与现有的标准比如asundexian.com相比.
主要方法:
- 对一种化合物进行了结构-活性关系 (SAR) 研究.
- 在体外测试中评估了FXIa抑制功效和选择性.
- 使用了体内血栓形成模型 (小鼠和的FeCl3诱导的动脉血栓形成).
- 在小鼠中评估出血风险和安全概况.
主要成果:
- 确定了几种强效和选择性FXIa抑制剂,包括化合物37,39b,43,和46b.
- 这些化合物表现出与asundexian相比的或更高的抗凝剂活性.
- 化合物43在体内显著降低了血栓形成,并且在不增加出血的情况下显示出良好的安全性.
结论:
- 新型基于pyridin-2(1H) 一的FXIa抑制剂显示出有前途的治疗潜力.
- 化合物43代表了治疗血栓形成的潜在候选者,其疗效和安全性已得到改善.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
592
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
592
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Therapeutic Index
4.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142


